[Laboratory and clinical evaluation of amikacin (BB-K8) (author's transl)].
D000328:Adult; D000368:Aged; D000613:Aminobutyrates / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000667:Ampicillin / Q000494:pharmacology; D002509:Cephaloridine / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D005839:Gentamicins / Q000494:pharmacology; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008826:Microbial Sensitivity Tests; D011014:Pneumonia / Q000188:drug therapy; D011549:Pseudomonas / Q000187:drug effects; D011704:Pyelonephritis / Q000188:drug therapy; D012475:Salmonella / Q000187:drug effects; D012760:Shigella / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
D000613:Aminobutyrates; D005839:Gentamicins; D007612:Kanamycin; D000667:Ampicillin; D002509:Cephaloridine